Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, the generic version of Celebrex of GD Searle, which is used for the treatment of Osteoarthritis and Rheumatoid Arthritis.
This is the first approval that the company has received from the US Food and Drug Administration (USFDA) during the current financial year. As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
